Skip to main content

Foundation Medicine, Clovis to Co-develop IVD for Drug Candidate

NEW YORK (GenomeWeb News) – Foundation Medicine and Clovis Oncology today announced a collaboration to develop an in vitro diagnostic test to identify cancer patients who may best respond to a Clovis drug candidate currently in phase I/II clinical development.

The companies will analyze genomic changes in tissue samples from patients in order to assess the possibility of developing an IVD method directed at Clovis' drug rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. Particularly, they said, they aim to identify the additional genetic mutations beyond those in germ-line and somatic BRCA associated with defective DNA repair and that may define tumor targets for rucaparib.

The collaboration may be able to increase the percentage of ovarian cancer patients potentially eligible for rucaparib therapy from 15 percent typically found in germ-line mutations of BRCA to about 40 percent to 50 percent who have DNA repair deficiencies due to somatic mutations in a variety of genes, Foundation and Clovis said.

Financial and other terms of the deal were not disclosed.

Today's deal marks the most recent between Foundation and a pharmaceutical firm in recent months in support of an oncology program, following agreements with Novartis, Array BioPharma, and Sanofi.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.